A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Anakinra (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Therapeutic Use
- 03 May 2016 Results assessing safety data of 5 years (n=43) published in the Rheumatology
- 11 May 2015 Status changed from suspended to discontinued, as reported by ClinicalTrials.gov.
- 25 Jun 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.